
Over the last 7 days, the Clinical Research and Equipment industry has dropped 5.4%, driven by a pullback from Locus Cell of 11%. The industry has fallen 9.0% in the last year.
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 12 Jun 2026 | NT$31.0b | NT$2.7b | -NT$746,869,000.00 | 21.5x | -41.5x | 11.7x |
| Sun, 10 May 2026 | NT$34.1b | NT$2.5b | -NT$764,028,000.00 | 21.6x | -44.7x | 13.5x |
| Tue, 07 Apr 2026 | NT$31.0b | NT$2.5b | -NT$767,980,000.00 | 20.5x | -40.3x | 12.4x |
| Thu, 05 Mar 2026 | NT$31.8b | NT$2.4b | -NT$692,870,000.00 | 19.3x | -45.9x | 13.1x |
| Sat, 31 Jan 2026 | NT$33.9b | NT$2.4b | -NT$689,929,000.00 | 24.3x | -49.1x | 13.9x |
| Mon, 29 Dec 2025 | NT$34.7b | NT$2.4b | -NT$670,921,000.00 | 24.1x | -51.7x | 14.2x |
| Wed, 26 Nov 2025 | NT$37.0b | NT$2.4b | -NT$670,921,000.00 | 18.8x | -55.2x | 15.1x |
| Fri, 24 Oct 2025 | NT$36.9b | NT$2.5b | -NT$870,437,000.00 | 18.4x | -42.4x | 15x |
| Sun, 21 Sep 2025 | NT$34.5b | NT$2.5b | -NT$870,437,000.00 | 20x | -39.6x | 14x |
| Tue, 19 Aug 2025 | NT$33.3b | NT$2.5b | -NT$819,216,000.00 | 19.7x | -40.6x | 13.6x |
| Thu, 17 Jul 2025 | NT$33.5b | NT$2.5b | -NT$600,003,000.00 | 22.6x | -55.8x | 13.6x |
| Sat, 14 Jun 2025 | NT$33.4b | NT$2.5b | -NT$600,003,000.00 | 23.5x | -55.7x | 13.6x |
| Mon, 12 May 2025 | NT$31.1b | NT$2.5b | -NT$539,009,000.00 | 22.8x | -57.7x | 12.6x |
| Wed, 09 Apr 2025 | NT$29.8b | NT$2.5b | -NT$536,440,000.00 | 22.7x | -55.5x | 12.1x |
| Fri, 07 Mar 2025 | NT$36.6b | NT$2.6b | -NT$854,432,000.00 | 23.7x | -42.8x | 14.3x |
| Sun, 02 Feb 2025 | NT$36.8b | NT$2.6b | -NT$854,432,000.00 | 23.5x | -43.1x | 14.4x |
| Tue, 31 Dec 2024 | NT$34.1b | NT$2.6b | -NT$854,432,000.00 | 22.4x | -40x | 13.3x |
| Thu, 28 Nov 2024 | NT$41.3b | NT$2.6b | -NT$854,432,000.00 | 23.6x | -48.4x | 16.1x |
| Sat, 26 Oct 2024 | NT$41.7b | NT$2.5b | -NT$712,402,000.00 | 24.8x | -58.6x | 16.6x |
| Mon, 23 Sep 2024 | NT$42.3b | NT$2.3b | -NT$836,610,000.00 | 22.1x | -50.6x | 18.6x |
| Wed, 21 Aug 2024 | NT$40.9b | NT$2.3b | -NT$836,610,000.00 | 22.5x | -48.9x | 18x |
| Fri, 19 Jul 2024 | NT$44.2b | NT$2.1b | -NT$797,765,000.00 | 34.4x | -55.5x | 20.7x |
| Sun, 16 Jun 2024 | NT$41.6b | NT$2.1b | -NT$797,765,000.00 | 33.1x | -52.1x | 19.5x |
| Tue, 14 May 2024 | NT$39.7b | NT$2.1b | -NT$893,893,000.00 | 32.4x | -44.4x | 18.6x |
| Thu, 11 Apr 2024 | NT$40.9b | NT$2.1b | -NT$903,875,000.00 | 31.2x | -45.2x | 19.4x |
| Sat, 09 Mar 2024 | NT$41.7b | NT$2.1b | -NT$611,249,000.00 | 32.5x | -68.3x | 20.2x |
| Mon, 05 Feb 2024 | NT$43.1b | NT$2.1b | -NT$610,218,000.00 | 33.1x | -70.7x | 20.8x |
| Wed, 03 Jan 2024 | NT$48.5b | NT$2.1b | -NT$610,218,000.00 | 33.3x | -79.4x | 23.3x |
| Fri, 01 Dec 2023 | NT$48.9b | NT$2.1b | -NT$610,218,000.00 | 33.4x | -80.2x | 23.6x |
| Sun, 29 Oct 2023 | NT$50.0b | NT$2.2b | -NT$497,769,000.00 | 31.8x | -100.4x | 22.5x |
| Tue, 26 Sep 2023 | NT$48.2b | NT$2.2b | -NT$497,769,000.00 | 31x | -96.9x | 21.7x |
| Thu, 24 Aug 2023 | NT$42.9b | NT$2.2b | -NT$497,769,000.00 | 30.9x | -86.1x | 19.3x |
| Sat, 22 Jul 2023 | NT$48.1b | NT$2.5b | -NT$274,767,000.00 | 43.1x | -175.2x | 19.6x |
| Mon, 19 Jun 2023 | NT$49.4b | NT$2.5b | -NT$274,767,000.00 | 44.1x | -179.8x | 20.1x |
-179.8x
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | -5.67% | |
| Healthcare | -2.51% | |
| Life Sciences | -5.36% | |
| Clinical Research and Equipment | -5.36% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6589 EirGenix | NT$44.85 | 1.1% +NT$151.3m | -27.8% | PS12x | |
| 6662 BioLASCO Taiwan | NT$30.20 | 2.4% +NT$17.9m | -10.4% | PE17.8x | |
| 6848 RBC Bioscience | NT$20.85 | 6.4% +NT$17.8m | 22.3% | PE12.6x |